As advances in biotechnology move from experimental concepts to clinical reality, European regulatory frameworks are evolving alongside them.
In a new Transplant International article, members of the ESOT Executive Committee explore how emerging technologies – including machine perfusion, ex situ organ engineering, xenotransplantation and regenerative medicine – are reshaping transplantation and challenging traditional regulatory frameworks.
The authors examine how European regulation is shifting towards more adaptive, risk-based approaches and discuss the challenges of supporting innovation while ensuring patient safety, appropriate oversight and robust evidence generation.
Olivier Thaunat, ESOT President 2025–2027, said:
“Transplantation is no longer confined to retrieval, preservation and implantation; it is becoming a continuous process of biological intervention. The future of transplantation will depend on our ability to build a regulatory framework that is as adaptive, integrated and self-correcting as the biology it aims to govern. The goal is not to trade speed for safety, but to balance them dynamically, ensuring that innovation progresses alongside robust evidence generation and responsible oversight.”
As transplantation increasingly converges with biotechnology, genetic engineering and regenerative medicine, the article contributes to an important discussion on how regulation can remain both adaptive and accountable in the face of scientific progress.
Read the full article today: https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16976/full